Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00
Provider: Zacks Investment Research Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Epizyme Inc announces pricing of public offering of common stock


Wednesday, 5 Feb 2014 08:00am EST 

Epizyme Inc:Says the pricing of its underwritten public offering of 4,492,679 shares of its common stock at a price of $29.25 per share before underwriting discounts.Says it is selling 3,000,000 shares of its common stock in this offering, and certain existing stockholders are selling 1,492,679 shares of common stock in this offering.Says the company will not receive any proceeds from the sale of shares by the selling stockholders.Says in addition, Epizyme has granted to the underwriters a 30-day option to purchase up to 673,901 additional shares of common stock, if any, at the public offering price, less the underwriting discount.Intends to use proceeds from the offering, together with its existing cash and cash equivalents, as follows.To fund the company's share of the global development costs of clinical development of EPZ-5676, including costs of expansion stage of its ongoing Phase 1 clinical trial of EPZ-5676 in MLL-r adult patients.Says also MLL-PTD adult patients and its planned Phase 1b clinical trial of EPZ-5676 in MLL-r pediatric patients;.To fund research and development to build the company's product platform and advance its pipeline of preclinical product candidates; and.For working capital and general corporate purposes.Says offering is expected to close on or about Feb. 10, 2014, subject to customary closing conditions. 

Company Quote

27.24
1.01 +3.85%
30 Oct 2014